Fierce Pharma

JULY 25, 2024

Large pharma companies are still looking for deals in China. AstraZeneca and Daiichi Sankyo's antibody-drug conjugate star Enhertu experienced a slow quarter. Large pharma companies are still looking for deals in China. AstraZeneca and Daiichi Sankyo's ADC star Enhertu slowed down.

Pharma Companies 76

Pharma Companies Antibody Drugs 76

BioSpace

SEPTEMBER 17, 2023

The deal is an expansion of an existing production agreement between the companies and just one of several deals with large pharma companies that the Korean biotech has scooped up this year.

Antibody 68

Antibody Manufacturing Pharma Companies Production 68

Fierce Pharma

AUGUST 20, 2024

After picking up the European rights to Eli Lilly’s Emgality and Rayvow late last year, women’s health outfit Organon is upping its migraine accord with the Big Pharma company.

Pharma Companies 78

Pharma Companies Marketing Antibody 78

pharmaphorum

NOVEMBER 30, 2020

Neutralising antibodies (NAbs) present a unique challenge to researchers looking to treat patients with AAV treatment. Cure Rare Disease’s Rich Horgan discusses the importance of preclinical NAbs screening and helping rare disease patients better understand their eligibility for gene therapies.

Gene Therapy 105

Gene Therapy Gene Antibody Clinical Trials 105

pharmaphorum

DECEMBER 8, 2020

AbCellera Biologics has been in the spotlight since coming up with Eli Lilly’s COVID-19 antibody drug bamlanivimab, and looks set to capitalise on that exposure with a sizeable initial public offering. The drug is also being tested in other trials, including a phase 3 study looking at its role in prevention of SARS-CoV-2 infection.

Drugs 111

Drugs Antibody FDA Approval Pharma Companies 111

Fierce Pharma

AUGUST 8, 2024

Three large pharma companies are locked in a high-stakes antibody-drug conjugate race. Three large pharma companies are locked in a high-stakes antibody-drug conjugate race. Merck and Daiichi Sankyo teamed up on a DLL3 T-cell engager. Merck and Daiichi Sankyo teamed up on a DLL3 T-cell engager. billion.

Pharma Companies 52

Pharma Companies Antibody Drugs 52

Fierce Pharma

AUGUST 15, 2024

The TROP2 antibody-drug conjugate race has heated up among three Big Pharma companies: Gi | In this week’s episode of “The Top Line,” Fierce executive editor Eric Sagonowsky chats with Angus Liu about his feature story on the three TROP2 front-runners.

Pharma Companies 59

Pharma Companies Antibody Drugs 59

pharmaphorum

DECEMBER 21, 2021

Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene. Pharma companies are looking at whether blocking TIGIT as well as PD-1/PD-L1 can improve the efficacy of cancer immunotherapy.

Drugs 98

Drugs Antibody Pharma Companies Development 98

BioPharma Reporter

SEPTEMBER 19, 2023

The big pharma company Bristol Myers Squibb (BMS) has recruited contract manufacturing and development organization (CDMO) Samsung Biologics to manufacture a commercial antibody cancer treatment until 2030.

Manufacturing 59

Manufacturing Contract Manufacturing Pharma Companies Antibody 59

pharmaphorum

APRIL 21, 2022

One of the leading companies in the bid to bring a new class of alpha-synuclein targeting drugs to market for Parkinson’s disease – AbbVie – is ducking out of the challenge. AZ/Takeda are meanwhile running phase 2 trials of their MEDI 1342 antibody candidate. Interest in the target has also prompted a flurry of licensing deals.

Antibody 97

Antibody Protein Gene Therapy Pharma Companies 97

pharmaphorum

AUGUST 18, 2020

This is a question that a consortium of European pharma companies hopes to answer as it aims to rapidly develop new therapies to combat the pandemic. The consortium aims to rapidly develop drugs to fight SARS-CoV-2 and find virus neutralising antibodies. But also included in the 77.7

Protein 121

Protein Pharma Companies RNA Drugs 121

XTalks

JANUARY 20, 2025

This strategic move transformed Actavis into one of the largest pharma companies globally, with a strong presence across branded, generic and over-the-counter (OTC) medicines. Actavis Acquisition of Allergan Deal value : $70.5

Marketing 104

Marketing Botox Life Science Pharma Companies 104

BioPharma Reporter

NOVEMBER 6, 2023

The big pharma company Bristol Myers Squibb (BMS) committed up to $180 million for a phase 1-ready antibody-drug conjugate (ADC) for the treatment of blood cancer from the U.S.-South South Korean biotech company Orum Therapeutics.

Protein 52

Protein Pharma Companies Antibody Drugs 52

Pharmaceutical Technology

SEPTEMBER 8, 2022

The increasing number of approvals of biologics over the years has increased the volume of contracts for innovator APIs and biologic-dose outsourcing.

Gene 100

Gene Marketing Vaccine Vaccination 100

The Pharma Data

DECEMBER 11, 2020

The test has been designed to quantitatively measure of immunoglobulin G (IgG) antibodies to aid clinicians in identifying patients with an immune Covid-19 response pre- and post-vaccination. As we follow individuals over the course of a year, we are repeatedly testing them for both virus and antibodies.”.

Antibody 52

Antibody Vaccine Vaccination Containment 52

XTalks

FEBRUARY 19, 2021

In the latest round of Amgen’s (NASDAQ: AMGN ) ongoing patent battle against Regeneron (NASDAQ: REGN ) and Sanofi over LDL-lowering PCSK9 (proprotein convertase subtilisin/kexin type 9) antibodies, the latter came out with a win last week. However, other companies, including Bristol Myers Squibb and Merck & Co.,

Antibody 85

Antibody Sales Trials Marketing 85

pharmaphorum

MARCH 15, 2022

A group of pharma companies and academic groups have joined forces with the Digital Medicine Society (DiMe) to develop standardised, digital clinical measures that can be used in the development of therapies for Alzheimer’s disease and related dementias.

Development 111

Development Pharma Companies Clinical Trials Clinical Trials 111

pharmaphorum

AUGUST 2, 2022

Antibody-drug conjugates are coming back to the fore, with talks of multi-billion dollar buyouts and a rapidly growing number of approvals. Antibody-drug conjugates (ADCs) are a class of biologic drugs designed for targeted treatment of cancer.

Marketing 98

Marketing Antibody Drugs Clinical Trials 98

pharmaphorum

FEBRUARY 9, 2022

The promise of this approach means that there is now a growing pipeline of potential cancer vaccines emerging from within the portfolios of larger pharma companies and biotechs. While therapeutic cancer vaccines are able to help the body identify particular proteins expressed by cancer cells and then to instigate an immune response.

Vaccine 134

Vaccine Vaccination Clinical Trials Clinical Trials 134

pharmaphorum

JUNE 16, 2021

California biotech Ambrx Biopharma is hoping to raise $126 million from a listing on the New York Stock Exchange (NYSE) that will be used in part to fund clinical development of ARX-788, its HER2-targeting antibody drug conjugate (ADC).

Antibody 59

Antibody Sales Drugs Trials 59

pharmaphorum

MAY 12, 2021

Lilly’s head of new therapeutic modalities, Andrew Adams, said that saRNAs are “a promising new technology, which will expand the breadth of Lilly’s RNA therapeutics platform and the targets we can pursue” The US pharma company has been building a presence in RNA medicines via a series of partnerships, including a $1.2

RNA 76

RNA Protein Drugs Pharma Companies 76

pharmaphorum

FEBRUARY 15, 2022

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 Lilly is thought to be the first pharma company to sign up to use the new camptothecin payload platform.

Antibody 52

Antibody Licensing Licensing Drugs 52

pharmaphorum

DECEMBER 6, 2022

$500 million upfront and a total deal value of up to $5 billion sounds like a deal made by a top-tier pharma company – but in fact it comes from diminutive biotech Summit Therapeutics.

Licensing 52

Licensing Licensing Antibody Clinical Trials 52

pharmaphorum

DECEMBER 21, 2020

It’s the first major partnership for Janux, which was set up in 2017, and could be the last to be organised by Merck’s R&D head Roger Perlmutter who is retiring from the big pharma company at the end of the year. billion alliance with Taiho and Astex for cancer antibodies, including a KRAS drug, and a $4.2

Immune Response 59

Immune Response Sales Antibody Drugs 59

pharmaphorum

JANUARY 25, 2022

The Toronto-based company already counts many of the world’s largest pharma companies among its customers, using its platform for a range of tasks such as improving reagent and antibody selection to help scientists run more successful experiments, drawing on data from published studies and organisations’ internal databases.

Life Science 52

Life Science Reagent Pharma Companies Scientist 52

pharmaphorum

JANUARY 29, 2021

While tanezumab is an antibody and has to be delivered by subcutaneous injection, AK1780 is orally bioavailable. Along with tanezumab and AK1780, Lilly is also developing LY3016859, an antibody that blocks two different cellular targets (TGF alpha and epiregulin), in phase 2 for chronic pain.

Licensing 52

Licensing Licensing Bioavailability Antibody 52

XTalks

MARCH 31, 2023

The current investigation builds on a project from 2020 when BMS set out on SpaceX’s CRS-21 to look at ways to improve crystallizing monoclonal antibodies to gain better insights into their structure and crystallization kinetics in microgravity with the overarching goal of improving drug formulation and delivery.

Protein 97

Protein Research Development Manufacturing 97

pharmaphorum

JANUARY 24, 2023

The future of R&D The Our Future Health project was funded from various bodies, but the pharma industry was willing to include £100 million of investment, in return for access and insights from the information gathered. The monoclonal antibody binds to the CD200R1 receptor, preventing the interaction of CD200 and CD200R1.

Genetics 98

Genetics Drugs Genome Project Biobanking 98

pharmaphorum

OCTOBER 20, 2021

The trial – which will be supported by pharma company Eisai and Ionian University in the US – will see if the test can identify people who have mild cognitive impairment (MCI) due to Alzheimer’s disease.

Trials 78

Trials Genome Genomics Bioinformatics 78

The Pharma Data

JANUARY 24, 2021

.–( BUSINESS WIRE )– Faze Medicines , a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced that it has appointed Philip Vickers, Ph.D., a company developing first-in-class therapeutic antibodies targeting the tumor microenvironment.

Medicine 52

Medicine Pharma Companies Gene Therapy Development 52

pharmaphorum

MAY 20, 2021

It identified almost 100 partnerships between AI vendors and large pharma companies for drug discovery since 2015, with numbers increasing over time and around 27 signed last year. Along with Exscientia, other players in the category include BenevolentAI, Atomwise, Recursion Pharma, and Insilico Medicine.

Drugs 69

Drugs Pharma Companies Clinical Trials Clinical Trials 69

Delveinsight

NOVEMBER 29, 2020

Key players such as Novartis , Annexin Pharmaceuticals , Gene Signal , Ocular Therapeutics , and Asclepix Therapeutics along with other pharma companies are investigating their candidates proactively in a quest to launch their therapies as soon as possible in the Retinal vein occlusion market.

Marketing 52

Marketing Drug Delivery Pharma Companies Clinical Trials 52

pharmaphorum

JUNE 2, 2021

The deal gives Amgen rights to the KHK4083 antibody in all countries except Kyowa’s home market of Japan, and is back-loaded with potential milestone payments worth another $850 million plus royalties on sales. Kyowa will co-promote the drug in the US if approved, with opt-in rights in some other countries as well.

Drugs 52

Drugs Licensing Licensing Sales 52

pharmaphorum

APRIL 28, 2022

Despite the inherent difficulties, major pharma companies do take aim at rare diseases, usually with dedicated units focusing on clusters of rare diseases that afflict the same part of the body. How big pharma tackles rare diseases. It’s a different business model, if you will,” Miquel said. “So So that is the trick.

Pharma Companies 59

Pharma Companies Branding Development Marketing 59

pharmaphorum

FEBRUARY 28, 2022

million) in the first half of its financial year ended November 30, 2021, slightly down on the same period of 2020 shortly after the company launched. It now counts five of the top 10 pharma companies as customers for its ImmunoINSIGHTS autoantibody profiling platform, and says it expects revenues for the full year to reach around £6 million.

Life Science 52

Life Science Pharma Companies Development Protein 52

pharmaphorum

JANUARY 18, 2022

Two Spanish pharma companies are joining forces to identify new oral treatments for immune-inflammatory skin diseases with high unmet medical needs. Almirall and IRB Barcelona (the Institute for Research in Biomedicine), will conduct research using molecular glue degraders, a new approach to the skin diseases under scrutiny.

Dermatology 52

Dermatology Protein Pharma Companies Research 52

Pharmaceutical Technology

JANUARY 15, 2023

In the first 2023 edition of the CMO Moves monthly series , Pharmaceutical Technology explores recent news stories on regulatory and reimbursement decisions in different countries, and the companies linked to their success and failures. Seagen has contracted the antibody drug conjugate’s (ADC) manufacturing to several companies.

Manufacturing 130

Manufacturing Packaging Packaging Contract Manufacturing 130